

Ernest H Choy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9316799/publications.pdf>

Version: 2024-02-01

206
papers

12,371
citations

28242

55
h-index

30058

103
g-index

215
all docs

215
docs citations

215
times ranked

14170
citing authors

#	ARTICLE	IF	CITATIONS
1	Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2005, 52, 3279-3289.	6.7	828
2	Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. <i>Rheumatology</i> , 2012, 51, v3-v11.	0.9	635
3	Translating IL-6 biology into effective treatments. <i>Nature Reviews Rheumatology</i> , 2020, 16, 335-345.	3.5	369
4	The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. <i>Rheumatology</i> , 2010, 49, 295-307.	0.9	320
5	The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2010, 2, 247-256.	1.2	245
6	Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. <i>Cell Reports</i> , 2019, 28, 2455-2470.e5.	2.9	241
7	Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. <i>Rheumatology</i> , 2014, 53, 2143-2154.	0.9	239
8	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 31-35.	0.5	224
9	Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 761-772.	0.5	219
10	Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. <i>Rheumatology</i> , 2010, 49, 15-24.	0.9	212
11	Fibromyalgia Syndrome Module at OMERACT 9: Domain Construct. <i>Journal of Rheumatology</i> , 2009, 36, 2318-2329.	1.0	209
12	A patient survey of the impact of fibromyalgia and the journey to diagnosis. <i>BMC Health Services Research</i> , 2010, 10, 102.	0.9	204
13	The role of sleep in pain and fibromyalgia. <i>Nature Reviews Rheumatology</i> , 2015, 11, 513-520.	3.5	203
14	Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. <i>Rheumatology</i> , 2011, 50, 518-531.	0.9	198
15	Clinical significance of Janus Kinase inhibitor selectivity. <i>Rheumatology</i> , 2019, 58, 953-962.	0.9	187
16	Synovial tissue research: a state-of-the-art review. <i>Nature Reviews Rheumatology</i> , 2017, 13, 463-475.	3.5	175
17	Fatigue in rheumatoid arthritis: time for a conceptual model. <i>Rheumatology</i> , 2011, 50, 1004-1006.	0.9	163
18	Overlapping Structural and Functional Brain Changes in Patients With Long-Term Exposure to Fibromyalgia Pain. <i>Arthritis and Rheumatism</i> , 2013, 65, 3293-3303.	6.7	162

#	ARTICLE	IF	CITATIONS
19	Remission and rheumatoid arthritis: Data on patients receiving usual care in twenty-four countries. <i>Arthritis and Rheumatism</i> , 2008, 58, 2642-2651.	6.7	156
20	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48.	0.5	153
21	Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. <i>Pain</i> , 2016, 157, 1836-1850.	2.0	152
22	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 305-317.	6.3	145
23	Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1679-1687.	0.5	138
24	Non-pharmacological interventions for fatigue in rheumatoid arthritis. <i>The Cochrane Library</i> , 2013, , CD008322.	1.5	134
25	Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1855-1860.	0.5	131
26	The problem of choice: current biologic agents and future prospects in RA. <i>Nature Reviews Rheumatology</i> , 2013, 9, 154-163.	3.5	130
27	Fibromyalgia syndrome. <i>Journal of Rheumatology</i> , 2007, 34, 1415-25.	1.0	129
28	Cognitive behavioural therapies for fibromyalgia. <i>The Cochrane Library</i> , 2017, 2017, CD009796.	1.5	125
29	Fibromyalgic rheumatoid arthritis and disease assessment. <i>Rheumatology</i> , 2010, 49, 924-928.	0.9	122
30	Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case-control comparison. <i>BMJ Open</i> , 2019, 9, e031365.	0.8	121
31	Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. <i>European Urology</i> , 2019, 76, 73-81.	0.9	117
32	Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: Data from the randomized, double-blind, COMBO-DN study. <i>Pain</i> , 2014, 155, 2171-2179.	2.0	109
33	Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1800-1805.	0.5	106
34	Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. <i>Nature Medicine</i> , 2022, 28, 1256-1268.	15.2	105
35	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 20-33.	0.5	104
36	The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial. <i>Arthritis and Rheumatology</i> , 2017, 69, 1969-1977.	2.9	103

#	ARTICLE	IF	CITATIONS
37	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.5	102
38	Interleukin-6 as a Multifunctional Regulator: Inflammation, Immune Response, and Fibrosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, S1-S5.	1.0	102
39	The Jak/STAT pathway: A focus on pain in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 278-284.	1.6	97
40	Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. <i>Lancet</i> , The, 2016, 388, 239-247.	6.3	95
41	C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 219-229.	1.6	95
42	Anxiety and depressive symptoms in fibromyalgia are related to poor perception of health but not to pain sensitivity or cerebral processing of pain. <i>Arthritis and Rheumatism</i> , 2010, 62, 3488-3495.	6.7	88
43	Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1642-1652.	0.5	85
44	Education, Self-Management, and Upper Extremity Exercise Training in People With Rheumatoid Arthritis: A Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2014, 66, 217-227.	1.5	82
45	Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 1885-1895.	0.9	82
46	Fibromyalgia and Chronic Pain Syndromes. <i>Clinical Journal of Pain</i> , 2016, 32, 737-746.	0.8	81
47	Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1078-1085.	0.5	76
48	Optimized Peptide-MHC Multimer Protocols for Detection and Isolation of Autoimmune T-Cells. <i>Frontiers in Immunology</i> , 2018, 9, 1378.	2.2	72
49	Content and Criterion Validity of the Preliminary Core Dataset for Clinical Trials in Fibromyalgia Syndrome. <i>Journal of Rheumatology</i> , 2009, 36, 2330-2334.	1.0	66
50	Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. <i>Rheumatology</i> , 2012, 51, 1226-1234.	0.9	66
51	Establishing a Core Domain Set to Measure Rheumatoid Arthritis Flares: Report of the OMERACT 11 RA Flare Workshop. <i>Journal of Rheumatology</i> , 2014, 41, 799-809.	1.0	65
52	Alterations in resting-state regional cerebral blood flow demonstrate ongoing pain in osteoarthritis: An arterial spin-labeled magnetic resonance imaging study. <i>Arthritis and Rheumatism</i> , 2012, 64, 3936-3946.	6.7	64
53	Defining Disease Phenotypes in Primary Care Electronic Health Records by a Machine Learning Approach: A Case Study in Identifying Rheumatoid Arthritis. <i>PLoS ONE</i> , 2016, 11, e0154515.	1.1	64
54	The Longitudinal Examination of Arthritis Pain (LEAP) study: relationships between weekly fluctuations in patient-rated joint pain and other health outcomes. <i>Journal of Rheumatology</i> , 2007, 34, 2291-300.	1.0	61

#	ARTICLE	IF	CITATIONS
55	Biologic interventions for fatigue in rheumatoid arthritis. The Cochrane Library, 2016, 2016, CD008334.	1.5	60
56	A Systematic Review and Mixed Treatment Comparison of the Efficacy of Pharmacological Treatments for Fibromyalgia. Seminars in Arthritis and Rheumatism, 2011, 41, 335-345.e6.	1.6	57
57	Transforming clinical trials in rheumatology: towards patient-centric precision medicine. Nature Reviews Rheumatology, 2020, 16, 590-599.	3.5	56
58	Updating the OMERACT Filter: Implications for Patient-reported Outcomes. Journal of Rheumatology, 2014, 41, 1011-1015.	1.0	54
59	Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. RMD Open, 2016, 2, e000225.	1.8	54
60	Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: results of an international phase 3 trial. Annals of the Rheumatic Diseases, 2012, 71, 935-942.	0.5	49
61	Pain Thresholds in Rheumatoid Arthritis: The Effect of Tender Point Counts and Disease Duration. Journal of Rheumatology, 2012, 39, 28-31.	1.0	48
62	Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT). Annals of the Rheumatic Diseases, 2019, 78, 465-472.	0.5	48
63	Anti cytokine therapy in chronic inflammatory arthritis. Cytokine, 2016, 86, 92-99.	1.4	47
64	The biology behind interleukin-6 targeted interventions. Current Opinion in Rheumatology, 2016, 28, 152-160.	2.0	46
65	Enhanced and persistent levels of interleukin (IL)-17+CD4+ T cells and serum IL-17 in patients with early inflammatory arthritis. Clinical and Experimental Immunology, 2013, 174, 292-301.	1.1	45
66	Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study. Annals of the Rheumatic Diseases, 2020, 79, 316-323.	0.5	43
67	Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials. Clinical Rheumatology, 2009, 28, 1035-1044.	1.0	41
68	Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary. Journal of Rheumatology, 2015, 42, 2185-2189.	1.0	40
69	Are the ACR 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria?. Autoimmunity Reviews, 2018, 17, 33-35.	2.5	40
70	Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study. Arthritis Care and Research, 2017, 69, 1484-1494.	1.5	39
71	Chimaeric anti-CD4 monoclonal antibody cross-linked by monocyte Fcγ3 receptor mediates apoptosis of human CD4 lymphocytes. European Journal of Immunology, 1993, 23, 2676-2681.	1.6	38
72	Systematic Review of Discriminating Power of Outcome Measures Used in Clinical Trials of Fibromyalgia. Journal of Rheumatology, 2008, 35, 2094-2105.	1.0	38

#	ARTICLE	IF	CITATIONS
73	Use of Two-Dimensional Gel Electrophoresis To Measure Changes in Synovial Fluid Proteins from Patients with Rheumatoid Arthritis Treated with Antibody to CD4. <i>Vaccine Journal</i> , 2001, 8, 105-111.	2.6	35
74	Clinical experience of IL-6 blockade in rheumatic diseasesâ€”Implications on IL-6 biology and disease pathogenesis. <i>Seminars in Immunology</i> , 2014, 26, 97-104.	2.7	35
75	Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 1107-1123.	0.6	35
76	Updating the OMERACT Filter: Implications of Filter 2.0 to Select Outcome Instruments Through Assessment of â€œTruthâ€” Content, Face, and Construct Validity. <i>Journal of Rheumatology</i> , 2014, 41, 1000-1004.	1.0	34
77	Clinical experience with inhibition of interleukin-6. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 405-415.	0.8	33
78	Remission in Early Rheumatoid Arthritis: Predicting Treatment Response. <i>Journal of Rheumatology</i> , 2012, 39, 470-475.	1.0	33
79	Functional Analysis of a Complement Polymorphism (rs17611) Associated with Rheumatoid Arthritis. <i>Journal of Immunology</i> , 2015, 194, 3029-3034.	0.4	33
80	EULAR recommendations for management of fibromyalgia. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e54-e54.	0.5	33
81	Evaluation of the Shortâ€”, Midâ€”, and Longâ€”Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 685-695.	2.9	33
82	B Cell Synovitis and Clinical Phenotypes in Rheumatoid Arthritis: Relationship to Disease Stages and Drug Exposure. <i>Arthritis and Rheumatology</i> , 2020, 72, 714-725.	2.9	33
83	Development and validation of a patient-based disease activity score in rheumatoid arthritis that can be used in clinical trials and routine practice. <i>Arthritis and Rheumatism</i> , 2008, 59, 192-199.	6.7	32
84	What Makes Patients with Fibromyalgia Feel Better? Correlations Between Patient Global Impression of Improvement and Changes in Clinical Symptoms and Function: A Pooled Analysis of 4 Randomized Placebo-controlled Trials of Duloxetine. <i>Journal of Rheumatology</i> , 2009, 36, 2517-2522.	1.0	32
85	Key Symptom Domains to Be Assessed in Fibromyalgia (Outcome Measures in Rheumatoid Arthritis) Tj ETQq1 1 0.784314 rgBT /Over 0,8 32	0.8	32
86	Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. <i>Rheumatology</i> , 2018, 57, 499-507.	0.9	32
87	Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 367-373.	1.6	32
88	Identifying the unmet information and support needs of women with autoimmune rheumatic diseases during pregnancy planning, pregnancy and early parenting: mixed-methods study. <i>BMC Rheumatology</i> , 2018, 2, 21.	0.6	32
89	Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe. <i>RMD Open</i> , 2018, 4, e000799.	1.8	31
90	Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter â€” Determining Validation Requirements. <i>Journal of Rheumatology</i> , 2016, 43, 208-213.	1.0	30

#	ARTICLE	IF	CITATIONS
91	The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review. <i>Drug Safety</i> , 2018, 41, 473-488.	1.4	30
92	Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1456-1466.	2.9	30
93	Drug use and toxicity in psoriatic disease: focus on methotrexate. <i>Journal of Rheumatology</i> , 2008, 35, 1454-7.	1.0	30
94	Lower Placebo Responses After Long-Term Exposure to Fibromyalgia Pain. <i>Journal of Pain</i> , 2017, 18, 835-843.	0.7	29
95	Fibromyalgia position paper. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 186-193.	0.4	29
96	Differential Binding of Sarilumab and Tocilizumab to IL-6R α and Effects of Receptor Occupancy on Clinical Parameters. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 714-724.	1.0	28
97	Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register. <i>Rheumatology</i> , 2018, 57, 1982-1990.	0.9	26
98	Pharmacologic Modulation of Hand Pain in Osteoarthritis: A Double-Blind Placebo-Controlled Functional Magnetic Resonance Imaging Study Using Naproxen. <i>Arthritis and Rheumatology</i> , 2015, 67, 741-751.	2.9	25
99	Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report. <i>Journal of Rheumatology</i> , 2017, 44, 1536-1543.	1.0	25
100	The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1320-1330.	1.6	25
101	The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 694-704.	0.4	24
102	Rheumatoid arthritis: non-tumor necrosis factor targets. <i>Current Opinion in Rheumatology</i> , 2005, 17, 242-246.	2.0	22
103	Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. <i>Rheumatology</i> , 2015, 54, 1050-1055.	0.9	22
104	Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1781-1787.	0.5	21
105	An evidence-based review of pregabalin for the treatment of fibromyalgia. <i>Current Medical Research and Opinion</i> , 2018, 34, 1397-1409.	0.9	21
106	Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets. <i>Journal of Rheumatology</i> , 2014, 41, 994-999.	1.0	20
107	Is Chronic Pain a Disease in Its Own Right? Discussions from a Pre-OMERACT 2014 Workshop on Chronic Pain. <i>Journal of Rheumatology</i> , 2015, 42, 1947-1953.	1.0	20
108	Evaluation of Patient-Rated Stiffness Associated With Fibromyalgia: A Post-Hoc Analysis of 4 Pooled, Randomized Clinical Trials of Duloxetine. <i>Clinical Therapeutics</i> , 2012, 34, 824-837.	1.1	19

#	ARTICLE	IF	CITATIONS
109	Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 699-708.	1.6	19
110	Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. <i>European Journal of Cancer</i> , 2020, 138, 202-211.	1.3	19
111	T cells in psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2007, 9, 437-441.	2.1	18
112	Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective. <i>Current Medical Research and Opinion</i> , 2010, 26, 965-975.	0.9	18
113	The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective. <i>Journal of Medical Economics</i> , 2012, 15, 481-492.	1.0	18
114	The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis. <i>Rheumatology</i> , 2014, 53, 1344-1346.	0.9	18
115	Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1800-1809.	2.9	18
116	Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations. <i>Health Technology Assessment</i> , 2019, 23, 1-130.	1.3	18
117	Segregating the Cerebral Mechanisms of Antidepressants and Placebo in Fibromyalgia. <i>Journal of Pain</i> , 2014, 15, 1328-1337.	0.7	17
118	Economic evaluation of a brief Education, Self-management and Upper Limb Exercise Training in People with Rheumatoid Arthritis (EXTRA) programme: a trial-based analysis. <i>Rheumatology</i> , 2015, 54, 302-309.	0.9	17
119	Neuropathic-like pain in psoriatic arthritis: evidence of abnormal pain processing. <i>Clinical Rheumatology</i> , 2019, 38, 3153-3159.	1.0	17
120	Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, v51-v55.	0.9	17
121	“Nobody knows, or seems to know how rheumatology and breastfeeding works”: Women's experiences of breastfeeding whilst managing a long-term limiting condition – A qualitative visual methods study. <i>Midwifery</i> , 2019, 78, 91-96.	1.0	16
122	Using Visual Timelines in Telephone Interviews: Reflections and Lessons Learned From the Star Family Study. <i>International Journal of Qualitative Methods</i> , The, 2020, 19, 160940692091367.	1.3	16
123	Furthering Our Understanding of Fatigue in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 1775-1777.	1.0	15
124	Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naïve patients with psoriatic arthritis. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 497-510.	0.6	15
125	Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor inhibitors: systematic literature review and network meta-analyses. <i>RMD Open</i> , 2019, 5, e000798.	1.8	14
126	Drug Treatment of Rheumatic Diseases in the 1990s. <i>Drugs</i> , 1997, 53, 337-348.	4.9	13

#	ARTICLE	IF	CITATIONS
127	Participantsâ€™ experiences of an Education, self-management and upper extremity eXercise Training for people with Rheumatoid Arthritis programme (EXTRA). <i>Physiotherapy</i> , 2017, 103, 430-438.	0.2	13
128	Anti-CD4 monoclonal antibodies in rheumatoid arthritis. <i>Seminars in Immunopathology</i> , 1998, 20, 261-273.	4.0	12
129	Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 669-671.	0.5	12
130	Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102849.	2.5	12
131	Variation in the use of biologics in the management of rheumatoid arthritis across the UK. <i>Current Medical Research and Opinion</i> , 2012, 28, 1733-1741.	0.9	11
132	Evaluation of the Disease Activity Score in Twentyâ€Eight Jointsâ€Based Flare Definitions in Rheumatoid Arthritis: Data From a Threeâ€Year Clinical Trial. <i>Arthritis Care and Research</i> , 2015, 67, 1762-1766.	1.5	11
133	Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients. <i>Rheumatology and Therapy</i> , 2017, 4, 57-69.	1.1	11
134	Fatigue in rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, v1-v2.	0.9	11
135	<p>Practice Advisory on the Appropriate Use of NSAIDs in Primary Care</p>. <i>Journal of Pain Research</i> , 2020, Volume 13, 1925-1939.	0.8	11
136	Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party. <i>Rheumatology and Therapy</i> , 2015, 2, 113-125.	1.1	10
137	Death Receptor 3 (TNFRSF25) Increases Mineral Apposition by Osteoblasts and Region Specific New Bone Formation in the Axial Skeleton of Male DBA/1 Mice. <i>Journal of Immunology Research</i> , 2015, 2015, 1-9.	0.9	10
138	AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS). <i>BMC Rheumatology</i> , 2019, 3, 19.	0.6	10
139	Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. <i>Rheumatology and Therapy</i> , 2021, 8, 1661-1675.	1.1	10
140	Harnessing CD8+CD28â€™ Regulatory T Cells as a Tool to Treat Autoimmune Disease. <i>Cells</i> , 2021, 10, 2973.	1.8	10
141	Inhibiting interleukin-6 in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2008, 10, 413-417.	2.1	9
142	Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 958-966.	1.6	9
143	The role of interleukin-6 trans-signalling on cardiovascular dysfunction in inflammatory arthritis. <i>Rheumatology</i> , 2021, 60, 2852-2861.	0.9	9
144	Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK. <i>Current Medical Research and Opinion</i> , 2007, 23, 3069-3078.	0.9	8

#	ARTICLE	IF	CITATIONS
145	Clinical and radiological features of rheumatoid arthritis in British black Africans. <i>Clinical Rheumatology</i> , 2007, 27, 97-100.	1.0	8
146	RADIATE: more treatment options for patients with an inadequate response to tumor necrosis factor antagonists. <i>Nature Clinical Practice Rheumatology</i> , 2009, 5, 66-67.	3.2	8
147	Harmonizing Pain Outcome Measures: Results of the Pre-OMERACT Meeting on Partnerships for Consensus on Patient-important Pain Outcome Domains Between the Cochrane Musculoskeletal Group and OMERACT. <i>Journal of Rheumatology</i> , 2015, 42, 1943-1946.	1.0	8
148	Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1056-1064.	0.9	8
149	Current treatments to counter sleep dysfunction as a pathogenic stimulus of fibromyalgia. <i>Pain Management</i> , 2016, 6, 339-346.	0.7	7
150	Interleukin 6: The biology behind the therapy. <i>Considerations in Medicine</i> , 2018, 2, 2-6.	0.0	7
151	Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz010.	0.3	7
152	Defining criteria for rheumatoid arthritis patient-derived disease activity score that correspond to Disease Activity Score 28 and Clinical Disease Activity Index based disease states and response criteria. <i>Rheumatology</i> , 2016, 55, 1954-1958.	0.9	6
153	The need for comparative data in spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 32.	1.6	6
154	Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group. <i>Journal of Rheumatology</i> , 2019, 46, 1406-1408.	1.0	6
155	Alterations to adipose tissue morphology during inflammatory arthritis is indicative of vasculopathy in DBA/1 mice. <i>Adipocyte</i> , 2017, 6, 87-101.	1.3	5
156	High baseline serum IL-6 identifies a subgroup of rheumatoid arthritis patients with rapid joint damage and clinical progression and predicts increased sarilumab treatment response. <i>Rheumatology</i> , 2019, 58, .	0.9	5
157	Anti-inflammatory and immunoregulatory effects of pinolenic acid in rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 992-1004.	0.9	5
158	Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison. <i>European Journal of Rheumatology</i> , 2019, 6, 113-121.	1.3	5
159	Biopsychosocial Rehabilitation for Inflammatory Arthritis and Osteoarthritis Patients: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Arthritis Care and Research</i> , 2023, 75, 423-436.	1.5	5
160	Serological investigation of IgG levels and subclasses in rheumatoid arthritis patients following ingestion of bovine type II collagen: results of a double blind, randomised controlled trial. <i>Clinical Rheumatology</i> , 2011, 30, 193-199.	1.0	4
161	Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs. <i>Advances in Therapy</i> , 2019, 36, 817-827.	1.3	4
162	Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. <i>European Urology Focus</i> , 2021, 7, 1084-1091.	1.6	4

#	ARTICLE	IF	CITATIONS
163	Research Recommendations Following the Discovery of Pain Sensitizing IgG Autoantibodies in Fibromyalgia Syndrome. <i>Pain Medicine</i> , 2022, 23, 1084-1094.	0.9	4
164	Diagnostic and therapeutic care pathway for fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 120-127.	0.4	4
165	Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis. <i>Cytokine</i> , 2004, 28, 158-161.	1.4	3
166	Clinical Domains of Fibromyalgia Syndrome: Determination through the OMERACT Process. <i>Journal of Musculoskeletal Pain</i> , 2010, 18, 380-386.	0.3	3
167	CD28 ^{hi} Cells Are Increased in Early Rheumatoid Arthritis and Are Linked With Cytomegalovirus Status. <i>Frontiers in Medicine</i> , 2020, 7, 129.	1.2	3
168	Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study. <i>BMC Rheumatology</i> , 2021, 5, 3.	0.6	3
169	Comparing the Impact of Symptoms and Health Care Experiences of People Who Have and Have Not Received a Diagnosis of Fibromyalgia: A Cross-sectional Survey Within the PACFiND Study. <i>Arthritis Care and Research</i> , 2022, 74, 1894-1902.	1.5	3
170	Functional MRI in rheumatic diseases with a focus on fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 114, 82-85.	0.4	3
171	Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	3
172	Non-tumor necrosis factor biological therapies for rheumatoid arthritis. <i>APLAR Journal of Rheumatology</i> , 2005, 8, 77-83.	0.2	2
173	New biologics for rheumatoid arthritis. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2011, 41, 234-237.	0.2	2
174	Response to Comment on "Functional Analysis of a Complement Polymorphism (rs17611) Associated with Rheumatoid Arthritis". <i>Journal of Immunology</i> , 2015, 195, 4-4.	0.4	2
175	Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky045.	0.3	2
176	Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018. <i>Journal of Rheumatology</i> , 2019, 46, 1355-1359.	1.0	2
177	Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: a systematic review following COSMIN guidelines. <i>RMD Open</i> , 2022, 8, e002093.	1.8	2
178	Shielding reduced incidence of COVID-19 in patients with inflammatory arthritis but vulnerability is associated with increased mortality. <i>Rheumatology</i> , 2022, 61, SI120-SI128.	0.9	2
179	Pinolenic acid exhibits anti-inflammatory and anti-atherogenic effects in peripheral blood-derived monocytes from patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
180	Does the Health Assessment Questionnaire predict 5-year quality of life in early RA?. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 380-381.	3.2	1

#	ARTICLE	IF	CITATIONS
181	Outcome measures in rheumatoid arthritis. Indian Journal of Rheumatology, 2013, 8, S31-S35.	0.2	1
182	179â€fNeuropathic-like pain is common in psoriatic arthritis. Rheumatology, 2018, 57, .	0.9	1
183	FR10106â€f...SARILUMAB AND TOCILIZUMAB RECEPTOR OCCUPANCY (RO), AND EFFECTS ON C-REACTIVE PROTEIN (CRP) LEVELS, IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA). , 2019, , .		1
184	007â€fRandomised, open labelled clinical trial to investigate synovial mechanisms determining response: resistance to rituximab versus tocilizumab in RA patients failing TNF inhibitor therapy. Rheumatology, 2020, 59, .	0.9	1
185	Cumulative patient-based disease activity monitoring in rheumatoid arthritis â€“ predicts sustained remission, flare and treatment escalation. Seminars in Arthritis and Rheumatism, 2020, 50, 749-758.	1.6	1
186	Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK. Rheumatology Advances in Practice, 2021, 5, rkab042.	0.3	1
187	Rheumatologists at a crossroads: blocking tumour necrosis factor or interleukin 6 in disease-modifying anti-rheumatic drug inadequate responder patients with rheumatoid arthritis. Rheumatology, 2021, 60, 4953-4955.	0.9	1
188	Feasibility, acceptability and change in health following a telephone-based cognitive behaviour therapy intervention for patients with axial spondyloarthritis. Rheumatology Advances in Practice, 2021, 5, rkaa063.	0.3	1
189	Fibromyalgia position paper. Clinical and Experimental Rheumatology, 2021, 39 Suppl 130, 186-193.	0.4	1
190	OA05â€fLower incidence of COVID-19 but higher mortality in patients with inflammatory arthritis compared to controls in Wales, United Kingdom: a population epidemiological study. Rheumatology, 2022, 61, .	0.9	1
191	Comparing methods for the diagnosis of fibromyalgia. Nature Clinical Practice Rheumatology, 2006, 2, 244-245.	3.2	0
192	The future of biological agents in the treatment of rheumatoid arthritis. International Journal of Clinical Rheumatology, 2014, 9, 475-486.	0.3	0
193	Ms. A.M. Taylor, et al reply. Journal of Rheumatology, 2016, 43, 826.2-827.	1.0	0
194	04.06â€f...Alterations to adipose tissue-associated vasculopathy during inflammatory arthritis causes vascular dysfunction in dba/1 mice that is resolved by anti-tnf treatment. , 2017, , .		0
195	001â€fDo patients with axial spondyloarthritis who meet research criteria for fibromyalgia benefit from biologic therapy?. Rheumatology, 2018, 57, .	0.9	0
196	167â€fCardiovascular risk in clinical subtypes of psoriatic arthritis. Rheumatology, 2018, 57, .	0.9	0
197	I048â€fMechanisms of development of fibromyalgia in the context of inflammatory arthritis. Rheumatology, 2019, 58, .	0.9	0
198	Using biologics safely. Rheumatology, 2019, 58, 1515-1516.	0.9	0

#	ARTICLE	IF	CITATIONS
199	OP0165â€¦EULAR RECOMMENDATIONS FOR THE DIAGNOSIS AND THE MANAGEMENT OF RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS DUE TO CANCER IMMUNOTHERAPY. , 2019, , .		0
200	Generalised musculoskeletal problems. Best Practice and Research in Clinical Rheumatology, 2019, 33, 101441.	1.4	0
201	P201â€¦Anti-inflammatory and immunologic actions of pinolenic acid in rheumatoid arthritis. Rheumatology, 2020, 59, .	0.9	0
202	Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies. Rheumatology International, 2020, 40, 747-755.	1.5	0
203	Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the TAIL study.. Journal of Clinical Oncology, 2020, 38, e21628-e21628.	0.8	0
204	Considering Immuno-autonomics in Stratifying Successful Treatment of Rheumatoid Arthritis with Tumor Necrosis Factor Inhibition: Comment on Cohen et al. Rheumatol Ther 2021 June 19. Rheumatology and Therapy, 2021, , 1.	1.1	0
205	Diagnostic and therapeutic care pathway for fibromyalgia. Clinical and Experimental Rheumatology, 2021, 39 Suppl 130, 120-127.	0.4	0
206	Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination. Clinical and Experimental Rheumatology, 2021, , .	0.4	0